P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)

P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)

Bibliographic Details
Main Authors:	Bruno Paiva, Anastasiia Zherniakova, Jorge Nuñez, Paula Rodríguez-Otero, Qian Shi, Nikhil Munshi, Brian Durie, Jesús San Miguel
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970708.04566.c4

Similar Items

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
by: Angelo Maiolino, et al.
Published: (2023-05-01)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
by: Rania Gaspo, et al.
Published: (2023-08-01)

Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)
by: Roger G. Owen
Published: (2019-06-01)

MRD negativity: considerations for older adults with multiple myeloma
by: Hira Mian, et al.
Published: (2023-11-01)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
by: David G. Coffey, et al.
Published: (2023-09-01)

P951: CLINICAL AND LABORATORY CHARACTERISTICS, COURSE AND OUTCOME OF COVID19 INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
by: A. Sretenovic, et al.
Published: (2022-06-01)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
by: Rodrigo Fonseca, et al.
Published: (2023-03-01)

Utility of flow cytometry screening before MRD testing in multiple myeloma
by: Vandana Panakkal, et al.
Published: (2023-04-01)

160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy
by: Tian Zhang, et al.
Published: (2023-11-01)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
by: Rodrigo Fonseca, et al.
Published: (2023-05-01)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
by: F. B. Askeland, et al.
Published: (2022-06-01)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
by: Katharina Kriegsmann, et al.
Published: (2020-08-01)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
by: Kazuhito Suzuki, et al.
Published: (2021-09-01)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
by: Radhika Bansal, et al.
Published: (2023-04-01)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
by: Jesus San-Miguel
Published: (2022-04-01)

Using PFS : First Choice /
by: 194764 Todd, Gail
Published: (1989)

Pfs :software made easy /
by: 300845 Townsend, Carl
Published: (1985)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
by: Susheel K. Singh, et al.
Published: (2021-10-01)

Will Mass Spectrometry Replace Current Techniques for Both Routine Monitoring and MRD Detection in Multiple Myeloma?
by: Katie L. Thoren
Published: (2021-12-01)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
by: Elisa Meddi, et al.
Published: (2023-02-01)

P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
by: Ilaria Vigliotta, et al.
Published: (2023-08-01)

PFS: Publisher for windows;self teaching guide /
by: 209310 Cavanaugh, Sean
Published: (1992)

PFS: Particle-Filter-Based Superpixel Segmentation
by: Li Xu, et al.
Published: (2018-05-01)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
by: Kelly M. Rausch, et al.
Published: (2023-07-01)

Transmission blocking immunity as observed in a feeder system and serological reactivity to Pfs 48/45 and Pfs230 in field sera
by: W. Roeffen, et al.
Published: (1994-01-01)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
by: Konstantinos Papadimitriou, et al.
Published: (2020-11-01)

P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
by: Mark J Levis, et al.
Published: (2023-08-01)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
by: Ing S. Tiong, et al.
Published: (2023-03-01)

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia
by: Vossough P, et al.
Published: (2005-07-01)

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia
by: P Vossough, et al.
Published: (2005-06-01)

mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
by: Puthupparampil V. Scaria, et al.
Published: (2024-01-01)

The travel narrative in the Gospel of Luke: Interpretation of Lk 9,51-19,28.
by: Gregory, A
Published: (2006)

Tensile Deformation and Fracture Behavior of Nickel-Based Superalloy DZ951G
by: Chenhao Guo, et al.
Published: (2021-04-01)

AC low frequency conductivity in PZT PFS ferroelectric ceramics
by: Osak Andrzej
Published: (2017-01-01)

MRD in AML: The Role of New Techniques
by: Maria Teresa Voso, et al.
Published: (2019-07-01)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
by: Madlen Jentzsch, et al.
Published: (2023-08-01)

Fresh and Hardened Properties of Brick Aggregate Concrete with Maximum Aggregate Sizes of 10 mm to 75 mm
by: Tarek Uddin Mohammed, et al.
Published: (2023-09-01)

P831: NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS
by: Jens Hillengass, et al.
Published: (2023-08-01)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01)

P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
by: Gil Fridberg, et al.
Published: (2023-08-01)